Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma in high-risk patients: A predictive model using contrast-enhanced ultrasound

Table 2 Comparison and univariate analysis of contrast-enhanced ultrasound features between intrahepatic cholangiocarcinoma and hepatocellular carcinoma n (%)

CEUS features	ICC1 (n = 62)	HCC1 (n = 55)	P value	OR	(95%CI)
Irregular shape	31 (50.0)	9 (16.4)	0.000	5.037	(2.002, 13.786)
Hyper-enhanced in arterial phase	55 (88.7)	54 (98.2)	0.065	0.147	(0.003, 1.210)
Hypo/iso-enhanced in arterial phase	7 (11.3)	1 (1.8)	0.065	6.783	(0.827, 314.886)
Hypo-enhanced in portal phase	61 (98.4)	40 (72.7)	0.000	22.391	(3.206, 973.549)
Hypo-enhanced in late phase	61 (98.4)	51 (92.7)	0.186	4.728	(0.449, 239.097)
Rim-enhancement	40 (64.5)	1 (1.8)	0.000	94.271	(14.202, 3946.676)
Early washout (< 60 s)	57 (91.9)	17 (30.9)	0.000	24.563	(8.022, 92.533)
Duration of enhancement (< 30 s)	49 (79.0)	11 (20)	0.000	14.614	(5.653, 41.160)
Tumor supply artery	12 (19.4)	29 (52.7)	0.000	4.581	(1.904, 11.618)
Peripheral circular artery or tumor capsule	2 (3.2)	14 (25.5)	0.000	10.060	(2.137, 95.937)
Intra-tumoral vein	36 (58.1)	2 (3.6)	0.000	35.556	(8.118, 327.503)
Obscure boundary of tumor	43 (69.4)	12 (21.8)	0.000	7.942	(3.268, 20.550)
Obscure boundary of intra-tumoral non-enhanced area	40 (64.5)	1 (1.8)	0.000	94.271	(14.202, 3946.676)
Marked washout	38 (61.3)	1 (1.8)	0.000	82.367	(12.448, 3454.264)

¹Data are number of cases, with percentages in parentheses. CEUS: Contrast-enhanced ultrasound; ICC: Intrahepatic cholangiocarcinoma; HCC: Hepatocellular carcinoma; OR: Odds ratio.